Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Chronic Myeloid Leukemia — Treatment

First-line Second-line Later-line SECOND-LINE THIRD-LINE / LATER Chronic myeloid leukemia (CML) Chronic phase · frontline Resistance / intolerance Accelerated / blast phase Low-risk Imatinib IRIS ↗ Int/high-risk 2nd-gen TKI (dasatinib/nilotinib) DASISION / ENESTnd ↗ Switch Alternate 2nd-gen TKI per mutation T315I Ponatinib PACE ↗ STAMP Asciminib ASCEMBL ↗ Curative-intent TKI ± chemo → allo transplant advanced phase